Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,353 Mln
P/E Ratio
68.8
P/B Ratio
3.1
Industry P/E
--
Debt to Equity
0.12
ROE
0.05 %
ROCE
4.53 %
Div. Yield
0 %
Book Value
0.87
EPS
0.04
CFO
$-443.93 Mln
EBITDA
$-1,210.77 Mln
Net Profit
$-952.44 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
HUTCHMED (China) - ADR
| 8.26 | 4.07 | 9.78 | -5.45 | -1.11 | -4.35 | -- |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
HUTCHMED (China) - ADR
| -20.28 | 22.53 | -57.87 | 9.56 | 27.72 | 8.58 | -41.25 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.64 | 200.22 | -- | 299.46 | |
| 7.00 | 177.35 | -- | -40.76 | |
| 1.66 | 162.64 | -- | -136.88 | |
| 0.56 | 20.76 | 5.77 | 33.7 |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company... offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong. Address: Cheung Kong Center, Hong Kong, Hong Kong Read more
Executive Chairman
Mr. Chi Keung To ACGI, B.Sc., M.B.A.
Executive Chairman
Mr. Chi Keung To ACGI, B.Sc., M.B.A.
Headquarters
Hong Kong
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of HUTCHMED (China) Limited - ADR stood at $ 1,274 Mln as on 31-Dec-24
The share price of HUTCHMED (China) Limited - ADR is $15.60 (NASDAQ) as of 22-Apr-2025 12:41 EDT. HUTCHMED (China) Limited - ADR has given a return of -1.11% in the last 3 years.
HUTCHMED (China) Limited - ADR has a market capitalisation of $ 2,353 Mln as on 21-Apr-2025. As per Value Research classification, it is a company.
The P/E ratio of HUTCHMED (China) Limited - ADR is 68.80 times as on 21-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the HUTCHMED (China) Limited - ADR and enter the required number of quantities and click on buy to purchase the shares of HUTCHMED (China) Limited - ADR.
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong. Address: Cheung Kong Center, Hong Kong, Hong Kong
The CEO & director of Mr. Chi Keung To ACGI, B.Sc., M.B.A.. is HUTCHMED (China) Limited - ADR, and CFO & Sr. VP is Mr. Chi Keung To ACGI, B.Sc., M.B.A..
There is no promoter pledging in HUTCHMED (China) Limited - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
18
|
|
|
16
|
|
|
2
|
| HUTCHMED (China) Limited - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
5.06
|
|
Operating margin(%)
|
0.28
|
|
Net Margin(%)
|
5.99
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of HUTCHMED (China) Limited - ADR was $0 Mln.
$1.71
(
